Bile Duct Neoplasms clinical trials

The registry lists 254 studies for Bile Duct Neoplasms across more than 10 countries. 44 are recruiting or about to start. 81 of them are mainly about Bile Duct Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.

Get an email when these change. Save the Bile Duct Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 125
Recruiting: 36
Status unknown: 31
Terminated: 28
Active, not recruiting: 15
Withdrawn: 8

Phase

Phase 2: 93
Phase 1: 65
Phase 3: 23
Phase 4: 10

Where

United States: 145
China: 24
Korea, Republic of: 24
Germany: 18
France: 18
Canada: 14

Who runs them

National Cancer Institute (NCI) (27) · Memorial Sloan Kettering Cancer Center (7) · Seoul National University Hospital (5) · Mayo Clinic (5) · National Institutes of Health Clinical Center (CC) (4) · Alliance for Clinical Trials in Oncology (4) · Weill Medical College of Cornell University (4) · Ajou University School of Medicine (3)

What is being tested here

Drugs under test in Bile Duct Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Gemcitabine	2	3	23
Tivozanib	2	0	2
Cisplatin	1	0	8
Ceralasertib	1	0	2
CDX-1140	1	0	2
Durvalumab	1	0	2
Desoxyepothilone B	1	0	1
Actinium-225	1	0	1
Immunocytokine NHS-IL12	1	0	1
Tislelizumab	1	0	1

Drug classes tested here Immune checkpoint inhibitors 4 open · Tyrosine kinase inhibitors (TKIs) 3 open · Antimetabolites 2 open · Antimitotic agents 1 open · Antiemetics 3

Coming up

1phase 3 study under way

17studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Dec 2026Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) · Nataliya Uboha
Dec 2026Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract · Memorial Sloan Kettering Cancer Center
Dec 2026Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types · University of Florida
Dec 2026Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio · Beth Israel Deaconess Medical Center
Dec 2026A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors · Shanghai Bao Pharmaceuticals Co., Ltd.
Dec 2026Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors · Beijing Biostar Pharmaceuticals Co., Ltd.
Dec 2026On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer · Region Skane
Dec 2026Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer · First Affiliated Hospital of Zhejiang University
Dec 2026A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors · Chongqing Precision Biotech Co., Ltd
Jan 2027Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents · Region Stockholm

Who these studies take

Of the 36 Bile Duct Neoplasms studies recruiting now, 21 (58%) set no upper age limit and 6 (17%) stop at 75 or younger. 1 (3%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (6%) take healthy volunteers.

Recruiting studies that take each age, of 36
Age	Women	Men
10	1 (3%)	1 (3%)
18	31 (86%)	31 (86%)
30	36 (100%)	36 (100%)
40	36 (100%)	36 (100%)
50	36 (100%)	36 (100%)
65	36 (100%)	36 (100%)
75	35 (97%)	35 (97%)
85	29 (81%)	29 (81%)

Across all 254 studies, recruiting or not: 8% stop at 75 or younger and <1% at 65; 7% take children; 0% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Bile Duct Neoplasms studies take

Of 23 phase 2 interventional studies under Bile Duct Neoplasms, half reached primary completion within 55 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	53 mo36–63 · 17 studies	—	—
Phase 2	55 mo35–73 · 23 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Started recruiting1

SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METOct 16, 2026NCT07873450

Newly registered1

SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-METOct 14, 2026NCT07873450

Studies

Recruiting first, then most recently updated. Showing 50 of 254. Browse all 254 → or search them.